scholarly journals Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials

2015 ◽  
Vol 41 (5) ◽  
pp. 1251-1260 ◽  
Author(s):  
Susan L McElroy ◽  
James Hudson ◽  
M Celeste Ferreira-Cornwell ◽  
Jana Radewonuk ◽  
Timothy Whitaker ◽  
...  
2020 ◽  
Author(s):  
Elnaz Moghimi ◽  
Caroline Davis ◽  
Michael Rotondi

BACKGROUND There has been a recent rise in the use of eHealth treatments for a variety of psychological disorders, including eating disorders. OBJECTIVE This meta-analysis of randomized controlled trials is the first to evaluate the efficacy of eHealth interventions specifically for the treatment of binge eating disorder (BED)– characterized by compulsive overconsumption of food, in a relatively short period of time and without compensatory behaviors like purging or fasting. METHODS A search on the electronic databases PubMed, Web of Science, Embase, Medline, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) was conducted for randomized controlled trials that compared the efficacy of eHealth treatment interventions to wait-list controls. From the databases searched, three studies met the inclusion criteria, and all the interventions administered were forms of internet-based guided cognitive behavioral therapy. RESULTS The results of the analysis demonstrate that when compared to wait list controls, eHealth interventions reduce objective binge episodes (OBE; SMD is -0.77, 95% CI, -1.38 to -0.16) and eating disorder psychopathology (SMD -0.71, 95% CI -1.20 to -0.22), which include shape (SMD -0.61, 95% CI -1.01 to -0.22) and weight concerns (SMD -0.91, 95% CI -1.33 to -0.48). There was no significant difference in body mass index between eHealth interventions and controls (SMD -0.01, 95% CI, -0.40 to 0.39). CONCLUSIONS These findings provide promising results for the use of internet-based CBT for BED treatment and support the greater need for future research to explore the efficacy of these eHealth interventions.


2017 ◽  
Vol 37 (3) ◽  
pp. 315-322 ◽  
Author(s):  
Maria Gasior ◽  
James Hudson ◽  
Javier Quintero ◽  
M. Celeste Ferreira-Cornwell ◽  
Jana Radewonuk ◽  
...  

2021 ◽  
pp. 1-9
Author(s):  
Janet A. Lydecker ◽  
Carlos M. Grilo

Abstract Background Psychiatric comorbidity is common in binge-eating disorder (BED) but effects on treatment outcomes are unknown. The current study aimed to determine whether psychiatric comorbidity predicted or moderated BED treatment outcomes. Methods In total, 636 adults with BED in randomized-controlled trials (RCTs) were assessed prior, throughout, and posttreatment by doctoral research-clinicians using reliably-administered semi-structured interviews, self-report measures, and measured weight. Data were aggregated from RCTs testing cognitive-behavioral therapy, behavioral weight loss, multi-modal (combined pharmacological plus cognitive-behavioral/behavioral), and/or control conditions. Intent-to-treat analyses (all available data) tested comorbidity (mood, anxiety, ‘any disorder’ separately) as predictors and moderators of outcomes. Mixed-effects models tested comorbidity effects on binge-eating frequency, global eating-disorder psychopathology, and weight. Generalized estimating equation models tested binge-eating remission (zero binge-eating episodes during the past month; missing data imputed as failure). Results Overall, 41% of patients had current psychiatric comorbidity; 22% had mood and 23% had anxiety disorders. Psychiatric comorbidity did not significantly moderate the outcomes of specific treatments. Psychiatric comorbidity predicted worse eating-disorder psychopathology and higher binge-eating frequency across all treatments and timepoints. Patients with mood comorbidity were significantly less likely to remit than those without mood disorders (30% v. 41%). Psychiatric comorbidity neither predicted nor moderated weight loss. Conclusions Psychiatric comorbidity was associated with more severe BED psychopathology throughout treatment but did not moderate outcomes. Findings highlight the need to improve treatments for BED with psychiatric comorbidities but challenge perspectives that combining existing psychological and pharmacological interventions is warranted. Treatment research must identify more effective interventions for BED overall and for patients with comorbidities.


2017 ◽  
Vol 27 (9) ◽  
pp. 1872-1876 ◽  
Author(s):  
Jacopo Giuliani ◽  
Andrea Bonetti

IntroductionIn ovarian cancer, it is uncertain which chemotherapy regimen is more clinically effective and cost-effective for the treatment of recurrence; therefore, it might be interesting to make a balance between the cost of the drugs administered and the difference in progression-free survival (PFS) and overall survival (OS).MethodsThe present evaluation was restricted to pivotal phase 3 randomized controlled trials. We calculated the pharmacological costs necessary to get the benefit in PFS and OS. The costs of drugs are at the pharmacy of our hospital and are expressed in Euros (€). We have subsequently applied the European Society for Medical Oncology Magnitude of Clinical Benefit Scale.ResultsOur study evaluated 3 phase 3 randomized controlled trials, including 2004 patients. The most relevant increase of costs was associated with the combination chemotherapy including trabectedin, with the highest costs for month of PFS gained (15,836 €) and for month of OS gained (7198 €), but it substantially differs considering the data of partially platinum-sensitive populations (platinum-free interval of 6–12 months), with 3959 € for month of OS gained.ConclusionsThe addition of trabectedin to pegylated liposomal doxorubicin for the treatment of recurrent ovarian cancer can lead to an increase of pharmacological costs. Differently, considering OS in patients with platinum-free interval of 6 to 12 months, there is a halving of pharmacological costs with the addition of trabectedin to pegylated liposomal doxorubicin. These costs are in line with the spending suggested as sustainable (thresholds of <$61,500 per life-year gained).


CNS Spectrums ◽  
2015 ◽  
Vol 20 (1) ◽  
pp. 61-92 ◽  

Congratulations to the scientific poster winners of the 2014 NEI Psychopharmacology Congress!1stPLACE: Randomized controlled safety and efficacy trials of lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder (page 14)2ndPLACE: CNS Pharmacology of Dextromethorphan (DM): New insights on potential mechanism of action and therapeutic applications (page 30)


Sign in / Sign up

Export Citation Format

Share Document